Exclusive coverage of the 2016 inaugural 'Inspiring Hope' Ideathon Views & Analysis Adam Jeffery 25 September, 2016 2016 Bookmark this
News Apogee rises as long-acting eczema drug heads for phase 3 Apogee shares have spiked on data showing strong efficacy with its atopic dermatitis drug and the potential for dosing just two to four times a year.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
R&D Deep Dive: Research and Development 2025 Every breakthrough in medicine, every new treatment that changes lives, starts with research.
R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Oncology On the forefront of healthcare change, turning innovative sc... Claus Zieler, chief commercial and medical affairs officer & member of the Executive Committee at Astellas Pharma, spoke with pharmaphorum at ASCO25.
Oncology Life Sciences Industry Report - Oncology Developments in the oncology space in 2024 brought hope to both industry and patients.
R&D Partner Content 16th World ADC San Diego 2025 The World’s Largest, Longest-Standing & Most Comprehensive Antibody-Drug Conjugate Conference
Digital Partner Content Axtria Ignite 2025: Leading in an Agentic Era Axtria’s flagship event is almost here! Axtria Ignite 2025 is taking place 4th to 5th June at the Princeton Marriott at Forrestal in New Jersey. This
Oncology On the forefront of healthcare change, turning innovative sc... Claus Zieler, chief commercial and medical affairs officer & member of the Executive Committee at Astellas Pharma, spoke with pharmaphorum at ASCO25.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face